Access to novel anti-diabetic agents in resource limited settings:A brief commentary

作     者：Poobalan Naidoo Kiolan Naidoo Sumanth Karamchand Rory F Leisegang 

作者机构：Department of Internal MedicineNelson R MandelaSchool of MedicineUniversity of Kwa-Zulu NatalDurban 4001Kwa-Zulu NatalSouth Africa Department of LawUniversity of South AfricaPretoria 3GautengSouth Africa Department of CardiologyUniversity of Stellenbosch and Tygerberg HospitalStellenbosch 7600Western CapeSouth Africa Department of PharmacometricsUpsala UniversityUppsala 75104Sweden 

出 版 物：《World Journal of Diabetes》 (世界糖尿病杂志（英文版）（电子版）)

年 卷 期：2023年第14卷第7期

页      面：939-941页

核心收录：

学科分类：1002[医学-临床医学] 08[工学] 0812[工学-计算机科学与技术（可授工学、理学学位）] 

主　　题：Type 2 diabetes mellitus Novel anti-diabetic agents Resource limited settings Access 

摘      要：The prevalence of diabetes mellitus is increasing in resource limited ***,there has been an increase in the number of novel therapies for the management of diabetes ***,use of novel antidiabetic therapies is limited because of major market access challenges in resource limited *** products to those patients with the highest absolute risk for major adverse cardiovascular outcomes,and thus most likely to benefit from the therapy,are less likely to have negative budget impact for *** improve access,and reduce morbidity and mortality,requires alignment amongst key stakeholders including patient advocacy groups,health care professional councils,national departments of health,the pharmaceutical industry,treasury and finance departments.